Swedish study links semaglutide and other GLP-1 drugs to fewer psychiatric hospitalizations in bipolar disorder

A nationwide Swedish study found that people with bipolar disorder were hospitalized for psychiatric reasons significantly less often during periods when they were taking GLP-1 medicines than during periods when they were not, according to researchers led by Professor Mark Taylor at Griffith University's School of Medicine and Dentistry ^[1]. The work is an observational analysis, which tracks what happens to people in ordinary care rather than testing a drug against a placebo, and no GLP-1 medicine is approved to treat a psychiatric condition ^[1].

The researchers analyzed health records for nearly 15,000 people with bipolar disorder who were prescribed GLP-1 medications, covering a 15-year period ^[1]. The comparison was between the same people at different times — when they were taking a GLP-1 medicine and when they were not — rather than between two separate groups of patients ^[1].

Taylor described the pattern in a statement: "People with bipolar disorder who were taking semaglutide (otherwise known as Ozempic or Wegovy), a type of GLP-1 medication, had significantly lower rates of psychiatric hospitalisation compared with periods when they were not taking GLP-1 medicines" ^[1]. Semaglutide is the molecule in Ozempic, Wegovy and Rybelsus; tirzepatide, sold as Mounjaro and Zepbound, is a different molecule and was not named in the report ^[1].

Several details that would help put the finding in context have not been reported, including the size of the difference between the two periods, the actual number of psychiatric hospitalizations in each period, which GLP-1 medicines beyond semaglutide were included, and how long patients were followed while on and off the drugs ^[1]. The report also does not say where the results were published, whether they have been peer reviewed, who funded the work, or what conflicts of interest the authors disclosed ^[1]. "Significant" in this context generally means the difference is unlikely to be explained by chance alone; it does not describe how large the difference was ^[1].

Why it matters for patients

Bipolar disorder can lead to repeated psychiatric hospitalizations, so a large study pointing to fewer of them is notable for patients and families who manage the condition over years ^[1]. The finding also arrives at a time when GLP-1 medicines are widely prescribed in the United States for diabetes and weight loss, so many people with bipolar disorder may already be taking one or discussing one with a clinician ^[1].

Observational analyses like this one cannot show that the medicine caused the difference ^[1]. Periods when a person is not taking a GLP-1 may differ in other ways — in overall health, access to care, or how closely they are being followed — and the report does not describe how the researchers accounted for those factors ^[1]. No GLP-1 medicine is approved for a psychiatric condition, and this result does not change any approved use ^[1].

The report does not address whether insurers would cover a GLP-1 for a psychiatric purpose, whether these medicines interact with mood stabilizers or other psychiatric drugs, or whether the pattern holds for patients outside Sweden ^[1]. Those questions have not been answered by this analysis ^[1].

What happens next

No next steps, follow-up studies or publication dates have been disclosed ^[1]. Researchers typically follow an observational signal like this with analyses that adjust for more variables or with randomized trials, but no such trial has been announced in the report ^[1].